Legend Biotech Statistics
Total Valuation
Legend Biotech has a market cap or net worth of $5.95 billion. The enterprise value is $5.17 billion.
Important Dates
The next confirmed earnings date is Tuesday, May 13, 2025, before market open.
| Earnings Date | May 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Legend Biotech has 183.65 million shares outstanding. The number of shares has increased by 3.84% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 183.65M |
| Shares Change (YoY) | +3.84% |
| Shares Change (QoQ) | +9.89% |
| Owned by Insiders (%) | 0.14% |
| Owned by Institutions (%) | 56.04% |
| Float | 80.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.34 |
| Forward PS | 5.75 |
| PB Ratio | 5.65 |
| P/TBV Ratio | 5.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.62, with a Debt / Equity ratio of 0.34.
| Current Ratio | 4.62 |
| Quick Ratio | 4.49 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.12 |
Financial Efficiency
Return on equity (ROE) is -15.45% and return on invested capital (ROIC) is -12.84%.
| Return on Equity (ROE) | -15.45% |
| Return on Assets (ROA) | -10.84% |
| Return on Invested Capital (ROIC) | -12.84% |
| Return on Capital Employed (ROCE) | -21.91% |
| Revenue Per Employee | $240,414 |
| Profits Per Employee | -$67,852 |
| Employee Count | 2,609 |
| Asset Turnover | 0.36 |
| Inventory Turnover | 29.91 |
Taxes
In the past 12 months, Legend Biotech has paid $18.89 million in taxes.
| Income Tax | 18.89M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.33% in the last 52 weeks. The beta is 0.20, so Legend Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -30.33% |
| 50-Day Moving Average | 34.27 |
| 200-Day Moving Average | 41.66 |
| Relative Strength Index (RSI) | 42.63 |
| Average Volume (20 Days) | 1,539,889 |
Short Selling Information
| Short Interest | 10.03M |
| Short Previous Month | 10.92M |
| Short % of Shares Out | 10.50% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.31 |
Income Statement
In the last 12 months, Legend Biotech had revenue of $627.24 million and -$177.03 million in losses. Loss per share was -$0.97.
| Revenue | 627.24M |
| Gross Profit | -20.88M |
| Operating Income | -305.15M |
| Pretax Income | -287.07M |
| Net Income | -177.03M |
| EBITDA | -294.29M |
| EBIT | -305.15M |
| Loss Per Share | -$0.97 |
Full Income StatementBalance Sheet
The company has $1.12 billion in cash and $350.60 million in debt, giving a net cash position of $772.08 million or $4.20 per share.
| Cash & Cash Equivalents | 1.12B |
| Total Debt | 350.60M |
| Net Cash | 772.08M |
| Net Cash Per Share | $4.20 |
| Equity (Book Value) | 1.04B |
| Book Value Per Share | 5.67 |
| Working Capital | 1.01B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$144.03 million and capital expenditures -$14.11 million, giving a free cash flow of -$158.14 million.
| Operating Cash Flow | -144.03M |
| Capital Expenditures | -14.11M |
| Free Cash Flow | -158.14M |
| FCF Per Share | -$0.86 |
Full Cash Flow StatementMargins
Gross margin is -3.33%, with operating and profit margins of -48.65% and -28.22%.
| Gross Margin | -3.33% |
| Operating Margin | -48.65% |
| Pretax Margin | -25.21% |
| Profit Margin | -28.22% |
| EBITDA Margin | -46.92% |
| EBIT Margin | -48.65% |
| FCF Margin | n/a |
Dividends & Yields
Legend Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.84% |
| Shareholder Yield | -3.84% |
| Earnings Yield | -2.98% |
| FCF Yield | -2.66% |
Dividend DetailsAnalyst Forecast
The average price target for Legend Biotech is $79.42, which is 145.12% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $79.42 |
| Price Target Difference | 145.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 36.93% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Legend Biotech has an Altman Z-Score of 7.83 and a Piotroski F-Score of 3.
| Altman Z-Score | 7.83 |
| Piotroski F-Score | 3 |